Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
$34.49
$34.46
$10.09
$37.00
$2.26B1.761.71 million shsN/A
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$3.93
-1.3%
$3.28
$1.07
$4.08
$1.05B0.883.17 million shs2.73 million shs
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$6.56
-6.0%
$6.67
$4.09
$17.24
$149.21M0.84282,861 shs189,465 shs
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$1.19
-4.0%
$1.01
$0.69
$3.94
$245.77M0.74.76 million shs2.09 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.35
-0.7%
$1.32
$1.21
$2.04
$1.08B1.343.87 million shs1.76 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
0.00%0.00%0.00%0.00%0.00%
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-1.26%+9.02%+10.08%+138.18%+263.89%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-6.02%-16.86%-17.48%+39.87%-55.07%
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-4.03%+1.62%-1.65%+16.67%-49.58%
OPKO Health, Inc. stock logo
OPK
OPKO Health
-0.74%+0.37%0.00%-4.59%+2.27%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
3.5743 of 5 stars
3.61.00.04.01.40.80.6
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
3.9118 of 5 stars
3.41.00.04.72.72.50.0
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
4.0345 of 5 stars
3.42.00.03.92.71.70.6
OPKO Health, Inc. stock logo
OPK
OPKO Health
4.1423 of 5 stars
3.50.00.04.42.93.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
0.00
N/AN/AN/A
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
3.20
Buy$6.7571.76% Upside
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
2.80
Moderate Buy$18.00174.39% Upside
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
2.80
Moderate Buy$7.00488.24% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
3.00
Buy$2.75103.70% Upside

Current Analyst Ratings Breakdown

Latest OPK, ENTA, AKBA, AIMT, and ESPR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/17/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/4/2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
6/3/2025
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$23.00 ➝ $24.00
5/7/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $4.00
5/1/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$2.25 ➝ $2.25
4/28/2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$7.00
4/25/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
4/25/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
4/25/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
N/AN/AN/AN/A$1.66 per shareN/A
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
$160.18M6.44N/AN/A($0.23) per share-17.09
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$67.64M2.07N/AN/A$6.08 per share1.08
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$332.31M0.71$0.02 per share51.61($1.97) per share-0.60
OPKO Health, Inc. stock logo
OPK
OPKO Health
$713.10M1.50$0.07 per share19.77$2.00 per share0.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
-$248.50M-$3.97N/AN/AN/AN/A-164.99%-89.50%N/A
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$69.41M-$0.21N/AN/AN/A-24.51%N/A-18.92%8/6/2025 (Estimated)
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$116.04M-$4.54N/AN/AN/A-149.57%-79.83%-26.65%8/4/2025 (Estimated)
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$51.74M-$0.80N/AN/AN/A-59.03%-0.91%-29.47%8/11/2025 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$53.22M-$0.07N/AN/AN/A-5.66%-2.85%-1.82%8/6/2025 (Estimated)

Latest OPK, ENTA, AKBA, AIMT, and ESPR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.11N/AN/AN/A$165.74 millionN/A
8/4/2025Q3 2025
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$1.10N/AN/AN/A$16.21 millionN/A
5/12/2025Q2 2025
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million
5/8/2025Q1 2025
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
-$0.03$0.03+$0.06$0.03$44.88 million$57.34 million
5/6/2025Q1 2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$0.18-$0.21-$0.03-$0.21$54.97 million$65.00 million
4/30/2025Q1 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.07-$0.10-$0.03-$0.10$163.13 million$149.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
N/AN/AN/AN/AN/A
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
N/AN/AN/AN/AN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/AN/AN/AN/AN/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
0.73
7.53
7.40
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
1.89
2.23
2.02
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/A
5.29
5.29
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/A
1.18
0.81
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.25
2.49
2.28

Institutional Ownership

CompanyInstitutional Ownership
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
74.47%
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
33.92%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
94.99%
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
47.39%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aimmune Therapeutics, Inc. stock logo
AIMT
Aimmune Therapeutics
22865.45 millionN/AOptionable
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
430262.64 million254.76 millionOptionable
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
16021.38 million18.41 millionOptionable
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
200198.20 million194.83 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
2,997793.05 million398.99 millionOptionable

Recent News About These Companies

Q1 2025 OPKO Health Inc Earnings Call

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aimmune Therapeutics stock logo

Aimmune Therapeutics NASDAQ:AIMT

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

Akebia Therapeutics stock logo

Akebia Therapeutics NASDAQ:AKBA

$3.93 -0.05 (-1.26%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$3.96 +0.02 (+0.64%)
As of 07/11/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Enanta Pharmaceuticals stock logo

Enanta Pharmaceuticals NASDAQ:ENTA

$6.56 -0.42 (-6.02%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$6.56 0.00 (-0.08%)
As of 07/11/2025 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Esperion Therapeutics stock logo

Esperion Therapeutics NASDAQ:ESPR

$1.19 -0.05 (-4.03%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.20 +0.01 (+0.42%)
As of 07/11/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.35 -0.01 (-0.74%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.37 +0.02 (+1.48%)
As of 07/11/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.